Rheumatology News

The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.

Biosimilars have generated billions of dollars of savings for the health care complex, but they have not had an impact on out-of-pocket expenses for patients with private insurance, according to findings published in JAMA Health Forum.

Pediatric rheumatology patients could be considered ready to transfer to adult care if they score greater than 4 on the Transition Readiness Assessment Questionnaire, according to data published in Rheumatology.

The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.

On May 8, the health care organization Ascension experienced a cyberattack that disrupted access to its electronic health care records, patient portals, phones and systems used to order tests, medications and procedures.

Financial independence is the holy grail, which affords one to work for the sake of working with the peace of mind of knowing they are no longer dependent on a paycheck to maintain their lifestyle.

Deucravacitinib is “very likely to be the best” targeted small-molecule drug for the treatment of systemic lupus erythematosus, according to data published in Arthritis Research & Therapy.

The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

CLEVELAND — Dermatology and rheumatology often work together in the treatment of psoriasis and psoriatic arthritis.